Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Harvard Business School
Boehringer Ingelheim
Dow
McKesson

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

MOTEGRITY Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Motegrity patents expire, and what generic alternatives are available?

Motegrity is a drug marketed by Shire Dev Llc and is included in one NDA.

The generic ingredient in MOTEGRITY is prucalopride succinate. One supplier is listed for this compound. Additional details are available on the prucalopride succinate profile page.

Drug patent expirations by year for MOTEGRITY
Drug Prices for MOTEGRITY

See drug prices for MOTEGRITY

Generic Entry Opportunity Date for MOTEGRITY
Generic Entry Date for MOTEGRITY*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for MOTEGRITY
0A09IUW5TP
179474-81-8
4-Amino-5-chloro-2,3-dihydro-benzofuran-7-carboxylic acid [1-(3-methoxy-propyl)-piperidin-4-yl]-amide
4-Amino-5-chloro-2,3-dihydro-N-(1-(3-methoxypropyl)-4-piperidyl)-7-benzofurancarboxamide
4-Amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide
4-Amino-5-chloro-N-(1-(3-methoxypropyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide
4-amino-5-chloro-N-[1-(3-methoxypropyl)-4-piperidyl]-2,3-dihydrobenzofuran-7-carboxamide
4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide
474P818
7-Benzofurancarboxamide, 4-amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-
7-Benzofurancarboxamide,4-amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-
A25458
AB0035840
AB1008449
AC-23945
AC1MHJYO
AK170477
AKOS015951096
AM84628
AN-3491
AS-19549
BCP02177
BCPP000099
BDBM50122872
C18H26ClN3O3
CAS-179474-81-8
CHEBI:135552
CHEMBL117287
CS-2574
D09205
DB06480
DSSTox_CID_31459
DSSTox_GSID_57670
DSSTox_RID_97345
DTXSID5057670
EX-A1333
FT-0674128
GTPL243
HMS3651F04
HY-14151
KS-000006NE
L000891
MolPort-009-679-441
NCGC00253867-01
NCGC00253867-02
PB31402
Prucalopride
Prucalopride (USAN/INN)
Prucalopride [USAN:INN:BAN]
prucalopride(r-93877)
PubChem22481
Q-3828
R 093877
R-093877
R093877
RL02293
s2875
SC-23104
SCHEMBL16952
SR-01000945275
SR-01000945275-1
SW219198-2
Tox21_113885
UNII-0A09IUW5TP
Y0251
ZINC1891034

US Patents and Regulatory Information for MOTEGRITY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire Dev Llc MOTEGRITY prucalopride succinate TABLET;ORAL 210166-001 Dec 14, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Shire Dev Llc MOTEGRITY prucalopride succinate TABLET;ORAL 210166-002 Dec 14, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Dow
Johnson and Johnson
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.